Lakeside Advisors INC. Has $1.60 Million Position in Novo Nordisk A/S (NYSE:NVO)

Lakeside Advisors INC. lowered its holdings in Novo Nordisk A/S (NYSE:NVO) by 2.1% during the fourth quarter, HoldingsChannel.com reports. The fund owned 18,650 shares of the company’s stock after selling 400 shares during the period. Novo Nordisk A/S accounts for 1.1% of Lakeside Advisors INC.’s portfolio, making the stock its 21st largest holding. Lakeside Advisors INC.’s holdings in Novo Nordisk A/S were worth $1,604,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Center for Financial Planning Inc. lifted its holdings in shares of Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after acquiring an additional 123 shares during the period. Daiwa Securities Group Inc. acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth about $28,000. Capital Performance Advisors LLP acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth about $42,000. Albion Financial Group UT lifted its holdings in Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after purchasing an additional 278 shares during the last quarter. Finally, Sound Income Strategies LLC boosted its position in Novo Nordisk A/S by 82.1% in the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock valued at $46,000 after buying an additional 243 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on NVO shares. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Stock Up 0.5 %

Shares of NVO opened at $83.79 on Friday. The business’s fifty day moving average price is $86.39 and its two-hundred day moving average price is $108.48. The firm has a market capitalization of $376.02 billion, a price-to-earnings ratio of 25.47, a PEG ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a 52 week low of $77.82 and a 52 week high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s payout ratio is 21.88%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.